Alzheimer's Drugs Arrived Brain Scanners Didn't with Jannis Fischer
MAR 31, 202643 MIN
Alzheimer's Drugs Arrived Brain Scanners Didn't with Jannis Fischer
MAR 31, 202643 MIN
Description
<p>Alzheimer's treatments finally exist but patients are waiting months for the brain scans they need to access them. In this episode, Jannis Fischer, CEO and co-founder of Positrigo, explains how his team built an ultra-compact brain PET scanner that fits inside a neurologist's office and cuts diagnostic timelines from months to days. From losing an investor the day before signing to FDA clearance and triple-digit patient volumes within weeks of launch, this is a founder story with real clinical stakes.</p><p><strong>Key Topics</strong></p><ul><li><p>Why new Alzheimer's drugs have created a brain PET bottleneck</p></li><li><p>How Positrigo's NeuroLF scanner delivers diagnostic-quality imaging in a seated, 10–20 minute scan</p></li><li><p>The "land and expand" go-to-market strategy across US neurology offices</p></li><li><p>Navigating FDA clearance and CE mark on ~€15M in funding</p></li><li><p>Transitioning from R&D organisation to customer-centric commercial operation</p></li><li><p>Fundraising a $25–35M growth round to scale from proof of concept to exit-readiness</p></li></ul><p><strong>Related Insights</strong></p><ul><li><p>Roche, Eli Lilly and Biogen are running trials on preventive Alzheimer's intervention blood tests could pre-screen patients before symptoms appear</p></li><li><p>The reimbursement landscape for brain PET is already settled existing codes apply, making the economics a "no-brainer" for neurology practices</p></li><li><p>Decentralising imaging from hospital centres to specialist offices mirrors the broader US trend in point-of-care diagnostics</p></li><li><p>Strategic acquirers (Siemens, GE Healthcare) and radiopharmaceutical synergies make trade sale the most likely exit path</p></li></ul><p><strong>Core Challenges</strong></p><ul><li><p>Whole-body PET systems are overloaded with oncology and cardiology scans, leaving neurology patients waiting months for brain imaging a bottleneck that worsens as Alzheimer's drug adoption accelerates.</p></li><li><p>Positrigo's NeuroLF system addresses this by enabling in-office brain PET scans at the point of care, but scaling requires the right sales team, operational partners, and growth capital to move from 3 installations to a nationwide footprint.</p></li></ul><p>🎧 Tune in now to hear how a particle physicist turned CEO is putting brain scanners where they belong next to the patients who need them most.</p><p><br></p><p>The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. </p><p><br></p><p>To learn more about Cruxx,<a href="https://www.thisiscruxx.com/"> click here.</a></p><p><br></p><p>A big thank you to our sponsors on this season of the podcast; </p><p><br></p><p><a href="https://www.linkedin.com/company/the-technology-partnership/">TTP plc</a> With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, <a href="https://www.linkedin.com/company/the-technology-partnership/">TTP plc</a> can accelerate your development with the latest technologies. Learn more at <a href="http://ttp.com/">TTP.com</a></p><p><br></p><p><br></p>